Digital medical services platform Teladoc Health (NYSE: TDOC) missed Wall Street’s revenue expectations in Q2 CY2026, with sales falling 4% year on year to $606.9 million. Next quarter’s revenue guidance of $589 million underwhelmed, coming in 6.5% below analysts’ estimates. Its GAAP loss of $0.21 per share was 17.4% above analysts’ consensus estimates.
Is now the time to buy Teladoc? Find out by accessing our full research report, it’s free.
Teladoc (TDOC) Q2 CY2026 Highlights:
- Revenue: $606.9 million vs analyst estimates of $615 million (4% year-on-year decline, 1.3% miss)
- EPS (GAAP): -$0.21 vs analyst estimates of -$0.25 (17.4% beat)
- Adjusted EBITDA: $65.71 million vs analyst estimates of $62.25 million (10.8% margin, 5.6% beat)
- The company dropped its revenue guidance for the full year to $2.4 billion at the midpoint from $2.53 billion, a 4.9% decrease
- EPS (GAAP) guidance for the full year is -$0.88 at the midpoint, beating analyst estimates by 4.2%
- EBITDA guidance for the full year is $287 million at the midpoint, above analyst estimates of $279.8 million
- Operating Margin: -6.1%, up from -8.6% in the same quarter last year
- Free Cash Flow Margin: 5.9%, up from 1.3% in the previous quarter
- Market Capitalization: $1.69 billion
“We continue to make progress on the priorities we believe are most important to the long-term success of Teladoc Health. Our second-quarter results were within our guidance ranges on a consolidated basis and reflected distinct dynamics across our two segments,” said Chuck Divita, Chief Executive Officer of Teladoc Health.
Company Overview
Founded to help people in rural areas get online medical consultations, Teladoc Health (NYSE: TDOC) is a telemedicine platform that facilitates remote doctor’s visits.
Revenue Growth
A company’s long-term performance is an indicator of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Unfortunately, Teladoc struggled to consistently increase demand as its $2.49 billion of sales for the trailing 12 months was close to its revenue three years ago. This wasn’t a great result and is a poor baseline for our analysis.
This quarter, Teladoc missed Wall Street’s estimates and reported a rather uninspiring 4% year-on-year revenue decline, generating $606.9 million of revenue. Company management is currently guiding for a 6% year-on-year decline in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 2% over the next 12 months. Although this projection implies its newer products and services will catalyze better top-line performance, it is still below average for the sector.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
Cash Is King
Although EBITDA is undoubtedly valuable for assessing company performance, we believe cash is king because you can’t use accounting profits to pay the bills.
Teladoc has shown impressive cash profitability, driven by its attractive business model that gives it the option to reinvest or return capital to investors. The company’s free cash flow margin averaged 10.3% over the last two years, better than the broader consumer internet sector.
Teladoc’s free cash flow clocked in at $35.74 million in Q2, equivalent to a 5.9% margin. The company’s cash profitability regressed as it was 8.4 percentage points lower than in the same quarter last year, prompting us to pay closer attention. Short-term fluctuations typically aren’t a big deal because investment needs can be seasonal, but we’ll be watching to see if the trend extrapolates into future quarters.
Key Takeaways from Teladoc’s Q2 Results
Revenue missed, revenue guidance for next quarter fell short of Wall Street’s estimates, and full-year revenue guidance was lowered, coming in below expectations. That overshadowed the positives such as an EBITDA beat. Overall, this was a softer quarter. The stock traded down 24.1% to $6.97 immediately following the results.
Teladoc’s earnings report left more to be desired. Let’s look forward to see if this quarter has created an opportunity to buy the stock. When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).
